

AUG 17 2010

USSN 10/646,308
Response to Office ActionIMMUNEX CORPORATION
Docket No. 3432-US-NP**LISTING OF THE CLAIMS**

This listing of claims represents the currently pending claims in the application. No amendments are presented in this listing of the claims, which is provided for the Examiner's convenience.

1.-45. (canceled)

46. (previously presented) A method for reducing chronic cardiotoxicity caused by a chemotherapeutic agent in a subject in need of such a treatment, comprising administering to the subject a 4-1BB antagonist in an amount sufficient to reduce the cardiotoxicity, wherein the 4-1BB antagonist is selected from the group consisting of a soluble 4-1BB protein that blocks or reduces the interaction of 4-1BB and 4-1BB-L, an antibody that specifically binds 4-1BB and blocks or reduces the interaction of 4-1BB and 4-1BB-L, and an antibody that specifically binds 4-1BB-L and blocks or reduces the interaction of 4-1BB and 4-1BB-L.

47. (previously presented) The method according to Claim 46, wherein the cardiotoxicity is cardiomyopathy.

48. (previously presented) The method according to Claim 46, wherein the chemotherapeutic agent is an anthracycline drug.

49. (previously presented) The method according to Claim 48, wherein the anthracycline drug is doxorubicin.

50. (canceled).

51. (previously presented) The method of Claim 46, wherein said soluble 4-1BB protein is an Fc fusion protein.

52. (previously presented) The method of Claim 46, wherein the subject is a cancer patient.

53.-63. (canceled)

USSN 10/646,308
Response to Office Action

IMMUNEX CORPORATION
Docket No. 3432-US-NP

64. (previously presented) The method of Claim 46, wherein the soluble 4-1BB protein is an oligomer.

65. (previously presented) The method of Claim 46, wherein the soluble 4-1BB protein comprises amino acids 1-163 of SEQ ID NO: 18.

66. (previously presented) The soluble 4-1BB protein of Claim 64, wherein the protein comprises amino acids 1-163 of SEQ ID NO: 18.

67. (previously presented) The soluble 4-1BB protein of Claim 51, wherein the protein comprises amino acids 1-163 of SEQ ID NO: 18.